Henry CAO
About Henry CAO
Henry CAO is the Senior Transactions Counsel at BeiGene in Shanghai, specializing in M&A within the life sciences sector.
Company
Henry CAO currently works at BeiGene as a Senior Transactions Counsel in Shanghai, China. BeiGene is a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Henry began his role at BeiGene in September 2023.
Title
Henry CAO holds the title of Senior Transactions Counsel. In this capacity, he engages in high-level legal and transactional work, specializing in mergers and acquisitions (M&A) and private equity (PE) transactions within the life sciences sector.
Education and Expertise
Henry CAO studied at the University of Pennsylvania Carey Law School and achieved a Master of Laws (LLM) in 2014. Prior to that, he received a Bachelor of Laws (LLB) from China University of Political Science and Law in 2013. Henry possesses extensive knowledge in accounting, economics, finance, and valuation, which supports his expertise in complex life sciences licensing deals and transactions.
Professional Background
Before joining BeiGene, Henry CAO worked at several prestigious law firms. He served as an Associate at Kirkland & Ellis from 2021 to 2023 in Shanghai, China. Prior to that, he was an Associate at Sidley Austin LLP from 2018 to 2021, also in Shanghai. Henry has also worked as a Foreign Legal Consultant at Latham & Watkins in Beijing from 2015 to 2018, and as an Associate at 君合律师事务所 in Beijing for a brief period in 2015.
Specialization in Life Sciences M&A
Henry CAO specializes in mergers and acquisitions (M&A) within the life sciences sector. His role involves negotiating, structuring, and executing complex transactions. Henry’s deep understanding of the sector's nuances, combined with his extensive legal and financial knowledge, makes him a key figure in facilitating licensing deals and strategic M&A activities.